Platelets in Thrombotic and Non-Thrombotic Disorders

Paolo Gresele is Guest Professor of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Italy Clive Page is Professor of Pharmacology at the Sackler Institute of Pulmonary Pharmacology and Therapeutics, Guy's, King's and St Thomas' School of Biomedical Sciences, London Jos Vermylen is Professor of Internal Medicine, University of Leuven, Belgium Valentin Fuster is Professor of Medicine, Mount Sinai Medical Center and School of Medicine, New York

Prologue; Part I. Physiology: 1. History of platelets; 2. Production of platelets; 3. Morphology and ultrastructure of platelets; 4. Platelet heterogeneity: physiology and pathological consequences; 5. Platelet membrane proteins as adhesion receptors; 6. Dynamics of the platelet cytoskeleton; 7. Platelet organelles; 8. Platelet receptors for thrombin; 9. Platelet receptors: ADP; 10. Platelet receptors: prostanoids; 11. Platelet receptors: collagen; 12. Platelet receptors: von Willebrand factor; 13. Platelet receptor: fibrinogen; 14. Platelet signalling: GTP-binding proteins; 15. Platelet phospholipases A2; 16. Roles of phospholipase C and phospholipase D in receptor-mediated platelet activation; 17. Platelet signalling: calcium; 18. Platelet signalling: protein kinase; 19. Platelet signalling: tyrosine kinases; 20. Platelet signalling: cAMP and cGMP; 21. Platelet adhesion; 22. The platelet shape change; 23. Aggregation; 24. Amplification loops: release reaction; 25. Amplification loops: thromboxane generation; 26. Platelet procoagulant activities: the amplification loops between platelets and the plasmatic clotting system; 27. Platelets and chemotaxis; 28. Platelet–leukocyte interactions relevant to vascular damage and thrombosis; 29. Vascular control of platelet function; Part II. Methodology: 30. In vitro assays for evaluating platelet functions; 31. Monitoring antiplatelet therapy; 32. Flow cytometric analysis of platelets function; 33. Animal models of platelet-dependent thrombosis; Part III. Pathology: A. Hemostasis: 34. Hereditary thrombocytopenias; 35. Thrombocytopenias due to bone marrow disorders; 36. Immune mediated thrombocytopenia; 37. Thrombocytopenia in childhood; 38. Alloimmune thrombocytopenia; 39. Drug-induced and drug-dependent immune thrombocytopenias; 40. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome; 41. Thrombocytosis and thrombocythemia; 42. Platelet adhesive protein defect disorders; 43. Congenital disorders of platelet secretion; 44. Congenital platelet signal transduction defects; 45. Acquired platelet function defects; 46. Platelet storage and transfusion; B. Thrombosis: 47. Phatophysiology of arterial thrombosis; 48. Platelets and atherosclerosis; 49. Platelet involvement in venous thrombosis and pulmonary embolism; 50. Gene regulation of platelet function; C. Non-hemostatic disorders: 51. Platelets and bacterial infections; 52. Interactions of viruses and platelets and the inactivation of viruses in platelet concentrates prepared for transfusion; 53. Platelets and parasites; 54. Platelets and tumours ; 55. Platelets and renal diseases; 56. Platelets and allergic diseases; 57. Platelet interactions with other cells related to inflammatory diseases; 58. Platelets and the preimplantation stage of embryo development; 59. Platelet in psychiatric and neurological disorders; 60. Platelets in inflammatory bowel disease; Part IV. Pharmacology: 61. Aspirin; 62. Pharmacology of ticlopidine clopidogrel; 63. Platelet membrane glycoprotein (GP) IIb1–IIIa antagonists and acute arterial thrombosis; 64. Other antiplatelet agents; 65. Pharmacogenetics as a new antiplatelet strategy; 66. Cardiovascular gene therapy: implications for platelet vessel wall interactions; 67. Pharmacological modulation of the inflammatory actions of platelets; Part V. Therapy: 68. Design of trials to evaluate antiplatelet agents; 69. Antiplatelet therapy in cardiology; 70. Antiplatelet therapies in neurology; 71. Antiplatelet treatment in peripheral vascular disease.